Morgan Stanley’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-810,795
| Closed | -$10.6M | – | 8299 |
|
|
2025
Q4 | $10.6M | Sell |
810,795
-53,610
| -6% | -$640K | ﹤0.01% | 3558 |
|
|
2025
Q3 | $6.29M | Buy |
864,405
+338,853
| +64% | +$2.29M | ﹤0.01% | 3957 |
|
|
2025
Q2 | $2.82M | Buy |
525,552
+325,527
| +163% | +$1.58M | ﹤0.01% | 4490 |
|
|
2025
Q1 | $1.07M | Buy |
200,025
+47,869
| +31% | +$335K | ﹤0.01% | 4971 |
|
|
2024
Q4 | $1.36M | Sell |
152,156
-77,555
| -34% | -$824K | ﹤0.01% | 4929 |
|
|
2024
Q3 | $2.53M | Buy |
229,711
+119,051
| +108% | +$1.32M | ﹤0.01% | 4482 |
|
|
2024
Q2 | $1.01M | Sell |
110,660
-114,895
| -51% | -$1.12M | ﹤0.01% | 4958 |
|
|
2024
Q1 | $3.17M | Sell |
225,555
-529,521
| -70% | -$6.59M | ﹤0.01% | 4272 |
|
|
2023
Q4 | $5.8M | Buy |
755,076
+721,726
| +2,164% | +$3.99M | ﹤0.01% | 4283 |
|
|
2023
Q3 | $249K | Sell |
33,350
-20,593
| -38% | -$176K | ﹤0.01% | 5484 |
|
|
2023
Q2 | $449K | Sell |
53,943
-29,906
| -36% | -$345K | ﹤0.01% | 5270 |
|
|
2023
Q1 | $1.12M | Buy |
83,849
+64,024
| +323% | +$866K | ﹤0.01% | 4799 |
|
|
2022
Q4 | $295K | Buy |
19,825
+9,120
| +85% | +$94K | ﹤0.01% | 5498 |
|
|
2022
Q3 | $97K | Buy |
10,705
+8,204
| +328% | +$55K | ﹤0.01% | 6087 |
|
|
2022
Q2 | $8K | Sell |
2,501
-507
| -17% | -$2.27K | ﹤0.01% | 7264 |
|
|
2022
Q1 | $20K | Sell |
3,008
-56
| -2% | -$333 | ﹤0.01% | 7145 |
|
|
2021
Q4 | $16K | Sell |
3,064
-5
| -0.2% | -$33 | ﹤0.01% | 7295 |
|
|
2021
Q3 | $28K | Sell |
3,069
-17,922
| -85% | -$172K | ﹤0.01% | 6955 |
|
|
2021
Q2 | $265K | Buy |
20,991
+3,344
| +19% | +$43.4K | ﹤0.01% | 5872 |
|
|
2021
Q1 | $306K | Sell |
17,647
-86,489
| -83% | -$1.56M | ﹤0.01% | 5410 |
|
|
2020
Q4 | $1.34M | Buy |
104,136
+103,818
| +32,647% | +$1.85M | ﹤0.01% | 4476 |
|
|
2020
Q3 | $12K | Sell |
318
-1,385
| -81% | -$54.9K | ﹤0.01% | 6206 |
|
|
2020
Q2 | $66K | Buy |
+1,703
| New | +$60.7K | ﹤0.01% | 5573 |
|
|
2020
Q1 | – | Sell |
-1,074
| Closed | -$38K | – | 6561 |
|
|
2019
Q4 | $38K | Buy |
1,074
+435
| +68% | +$13.7K | ﹤0.01% | 5933 |
|
|
2019
Q3 | $21K | Buy |
+639
| New | +$25.3K | ﹤0.01% | 5986 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 6706 |
|
|
2018
Q2 | – | Sell |
-60
| Closed | -$5.53K | – | 6660 |
|
|
2018
Q1 | $7K | Sell |
60
-57
| -49% | -$5.7K | ﹤0.01% | 6333 |
|
|
2017
Q4 | $11K | Buy |
117
+30
| +34% | +$3.53K | ﹤0.01% | 6196 |
|
|
2017
Q3 | $11K | Buy |
87
+6
| +7% | +$500 | ﹤0.01% | 6149 |
|
|
2017
Q2 | $7K | Sell |
81
-15
| -16% | -$1.25K | ﹤0.01% | 6295 |
|
|
2017
Q1 | $9K | Sell |
96
-62
| -39% | -$8.54K | ﹤0.01% | 6246 |
|
|
2016
Q4 | $35K | Buy |
158
+125
| +379% | +$30.6K | ﹤0.01% | 5843 |
|
|
2016
Q3 | $12K | Sell |
33
-10
| -23% | -$2.63K | ﹤0.01% | 6068 |
|
|
2016
Q2 | $10K | Buy |
43
+35
| +438% | +$10.5K | ﹤0.01% | 6057 |
|
|
2016
Q1 | $3K | Buy |
8
+6
| +300% | +$2.07K | ﹤0.01% | 6354 |
|
|
2015
Q4 | $1K | Sell |
2
-11
| -85% | -$5.28K | ﹤0.01% | 6555 |
|
|
2015
Q3 | $7K | Buy |
+13
| New | +$9.28K | ﹤0.01% | 6324 |
|
Morgan Stanley's ATXS Position: Q1 2026 in Review
Morgan Stanley sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 810,795 shares — an estimated $10.6M sold.
Morgan Stanley first reported a position in ATXS in Q3 2015 and held it in 36 quarters. The position peaked at $10.6M in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- Morgan Stanley reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- Morgan Stanley sold 810,795 Astria Therapeutics shares in Q1 2026, an estimated $10.6M.
- Morgan Stanley first reported a position in Astria Therapeutics in Q3 2015 and held it in 36 quarters.
- Morgan Stanley's Astria Therapeutics position peaked at $10.6M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.